Effective oral chemotherapy for breast cancer: pillars of strength.
about
Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancerPhase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts.Acceptance of oral chemotherapy in breast cancer patients - a survey study.Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.A Systematic Review of Adherence to Oral Antineoplastic TherapiesPolymeric nanoparticle drug delivery technologies for oral delivery applications.Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study.A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial.Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.Sorafenib in locally advanced or metastatic breast cancer.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Adherence to oral antineoplastic agents by cancer patients: definition and literature review.Plant natural products: from traditional compounds to new emerging drugs in cancer therapy.pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms.G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.Comparative adherence to oral hormonal agents in older women with breast cancer.Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada.All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.The oral education clinic: A pharmacist- and nurse-led clinic to support patients starting oral systemic anti-cancer treatments.Defining what matters most to patients.National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study.Improving patient care: expert nursing and service development.Current treatment of HER 2+ metastatic breast cancer.
P2860
Q24615262-209EEED3-C504-447E-8645-4B962CBA9F8AQ33408664-5CA175F4-2984-476E-83C0-957747E4CBC7Q33847820-CB7964B5-3F23-4737-B43A-F10F8B2C3C3EQ33870472-15A25FE4-21AE-4184-97CC-B5F12E97D3CCQ34096083-A85B1D06-BD70-4A3B-82B5-30FA597ADDB1Q36673490-0781DE01-A2F1-435C-9E46-7150A345EBC1Q36808308-0FAA7E37-C8E6-4E18-A06F-9261839A819AQ37029891-4DC32CAD-C0B1-4443-A53D-6E0E008817F7Q37048596-D0D3AB13-1BD3-4CD5-8163-5A40F5D0391CQ37287394-DA6896FE-1B14-4A68-862E-A0BAE64A6839Q37669505-7F025A25-EB25-4DA1-94C4-9FF45A7ED3D3Q37965653-6BD66BC5-C4BD-4E87-9F8D-FEAABF9DF16BQ38012156-F5E46871-23EE-43A8-BF5F-011A315BA1FAQ38082728-DADCE28E-1BA9-47EC-9075-B0B463EE889BQ38147533-D4B1B0AA-5642-4BF7-812A-40EF83AA5CD6Q38265836-BFE39A45-2B72-4383-B5FC-7CCCD624D4ACQ38757836-7C973A23-570F-4938-80E3-5D260023C431Q39626315-3CC7B913-53DC-4C36-8220-660687B90A60Q39906054-D970BD60-1953-4357-8F10-BA43A8E4E034Q40810672-F643D7E3-BE1F-445B-B9A8-A9FF67B1FBD5Q41674328-97DA625B-F596-4F28-B42E-3CAFCF312C26Q44802035-7116A980-54AE-492A-A7C5-5CFDDAEE0987Q46583399-00677B5E-FB16-439E-A346-D0766FF017E3Q47288134-FB4C1895-9EE1-49A2-BD37-03B620543316Q47665955-A8597BFB-B8EB-4FF2-B4F6-BDC1B1DAA3F0Q48296939-93516AB1-A67A-48F6-9D07-9CFAE77621C0Q49581531-A9CC82A7-CF87-47A7-9DD7-DDAEED14FD23Q49581539-8434B371-8AA8-4A3B-8006-9B99E4B00FCD
P2860
Effective oral chemotherapy for breast cancer: pillars of strength.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Effective oral chemotherapy for breast cancer: pillars of strength.
@en
Effective oral chemotherapy for breast cancer: pillars of strength.
@nl
type
label
Effective oral chemotherapy for breast cancer: pillars of strength.
@en
Effective oral chemotherapy for breast cancer: pillars of strength.
@nl
prefLabel
Effective oral chemotherapy for breast cancer: pillars of strength.
@en
Effective oral chemotherapy for breast cancer: pillars of strength.
@nl
P356
P1433
P1476
Effective oral chemotherapy for breast cancer: pillars of strength
@en
P2093
P304
P356
10.1093/ANNONC/MDM285
P577
2007-11-15T00:00:00Z